Compare Stocks: LENZ, GYRE, RLMD, and EOLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EOLS Evolus	$6.96 -3.1%	$7.62	$3.86 ▼ $9.31	$475.23M	1.38	1.09 million shs	455,367 shs
GYRE Gyre Therapeutics	$4.31 +0.2%	$6.30	$3.97 ▼ $9.14	$495.88M	2.14	198,048 shs	278,991 shs
LENZ LENZ Therapeutics	$4.13 +1.0%	$3.80	$2.80 ▼ $32.13	$128.51M	0.78	1.23 million shs	748,571 shs
RLMD Relmada Therapeutics	$4.21 +1.2%	$3.77	$3.07 ▼ $8.00	$443.75M	0.62	1.68 million shs	1.74 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EOLS Evolus	-3.06%	+2.35%	-3.60%	-14.60%	-4.66%
GYRE Gyre Therapeutics	+0.23%	-9.45%	-33.38%	-35.48%	-48.32%
LENZ LENZ Therapeutics	+0.98%	+18.00%	+20.41%	-12.68%	-83.80%
RLMD Relmada Therapeutics	+1.20%	+7.95%	+29.94%	-12.29%	+7.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EOLS Evolus	$6.96 -3.1%	$7.62	$3.86 ▼ $9.31	$475.23M	1.38	1.09 million shs	455,367 shs
GYRE Gyre Therapeutics	$4.31 +0.2%	$6.30	$3.97 ▼ $9.14	$495.88M	2.14	198,048 shs	278,991 shs
LENZ LENZ Therapeutics	$4.13 +1.0%	$3.80	$2.80 ▼ $32.13	$128.51M	0.78	1.23 million shs	748,571 shs
RLMD Relmada Therapeutics	$4.21 +1.2%	$3.77	$3.07 ▼ $8.00	$443.75M	0.62	1.68 million shs	1.74 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EOLS Evolus	-3.06%	+2.35%	-3.60%	-14.60%	-4.66%
GYRE Gyre Therapeutics	+0.23%	-9.45%	-33.38%	-35.48%	-48.32%
LENZ LENZ Therapeutics	+0.98%	+18.00%	+20.41%	-12.68%	-83.80%
RLMD Relmada Therapeutics	+1.20%	+7.95%	+29.94%	-12.29%	+7.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EOLS Evolus	2.50	Moderate Buy	$15.00	115.52% Upside
GYRE Gyre Therapeutics	1.50	Reduce	N/A	N/A
LENZ LENZ Therapeutics	2.43	Hold	$14.75	257.14% Upside
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	185.04% Upside

Current Analyst Ratings Breakdown

Latest LENZ, GYRE, RLMD, and EOLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/5/2026	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$13.00 ➝ $15.00
11/5/2026	LENZ LENZ Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$10.00 ➝ $9.00
11/4/2026	GYRE Gyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/30/2026	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$16.00
10/19/2026	LENZ LENZ Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$7.00 ➝ $5.00
10/19/2026	LENZ LENZ Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$7.00 ➝ $5.00
10/6/2026	GYRE Gyre Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
9/14/2026	RLMD Relmada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/11/2026	EOLS Evolus	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/9/2026	LENZ LENZ Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	LENZ LENZ Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 11/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EOLS Evolus	$325.47M	1.42	N/A	N/A	($0.57) per share	-12.21
GYRE Gyre Therapeutics	$110.06M	4.52	$0.22 per share	19.35	$1.25 per share	3.45
LENZ LENZ Therapeutics	$19.09M	6.80	N/A	N/A	$6.11 per share	0.68
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EOLS Evolus	-$51.64M	-$0.47	N/A	63.27	N/A	-9.56%	N/A	-11.10%	N/A
GYRE Gyre Therapeutics	$5.03M	-$0.20	N/A	N/A	N/A	-14.80%	-7.39%	-5.74%	N/A
LENZ LENZ Therapeutics	-$82.13M	-$4.49	N/A	N/A	N/A	-1,134.97%	-59.56%	-54.75%	N/A
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-38.51%	-35.94%	N/A

Latest LENZ, GYRE, RLMD, and EOLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	RLMD Relmada Therapeutics	-$0.1450	-$0.12	+$0.0250	-$0.12	N/A	N/A
11/5/2026	Q3 2026	GYRE Gyre Therapeutics	-$0.15	$0.04	+$0.19	$0.0030	$28.40 million	$32.93 million
10/28/2026	Q3 2026	LENZ LENZ Therapeutics	-$0.8932	-$0.99	-$0.0968	-$0.99	$4.20 million	$3.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EOLS Evolus	N/A	1.42	0.84
GYRE Gyre Therapeutics	N/A	4.32	3.86
LENZ LENZ Therapeutics	N/A	11.66	11.39
RLMD Relmada Therapeutics	N/A	29.52	29.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EOLS Evolus	90.69%
GYRE Gyre Therapeutics	23.99%
LENZ LENZ Therapeutics	54.32%
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
EOLS Evolus	5.00%
GYRE Gyre Therapeutics	9.50%
LENZ LENZ Therapeutics	8.30%
RLMD Relmada Therapeutics	14.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EOLS Evolus	365	66.19 million	62.88 million	Optionable
GYRE Gyre Therapeutics	618	115.32 million	104.37 million	Optionable
LENZ LENZ Therapeutics	152	31.42 million	28.81 million	Optionable
RLMD Relmada Therapeutics	17	106.67 million	91.20 million	Optionable

LENZ, GYRE, RLMD, and EOLS Headlines

Recent News About These Companies

Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

November 13 at 9:51 AM | marketscreener.comM

Relmada (RLMD) Q3 2026 Earnings Call Transcript

November 13 at 9:51 AM | finance.yahoo.com

What Relmada Therapeutics (RLMD) Said on Its Q3 Earnings Call

November 12 at 12:13 AM | marketbeat.com

Relmada Therapeutics, Inc. (RLMD) Q3 2026 Earnings Call Transcript

November 12 at 11:00 PM | seekingalpha.com

Relmada Therapeutics (NASDAQ:RLMD) Releases Quarterly Earnings Results

November 12 at 10:10 PM | marketbeat.com

Relmada Therapeutics Q3 Loss Narrows

November 12 at 6:35 PM | marketscreener.comM

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

November 12 at 4:05 PM | globenewswire.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock Has Average Price Target of $12.00 According to Analysts

November 5, 2026 | americanbankingnews.com

Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London

November 4, 2026 | globenewswire.com

Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026

November 3, 2026 | globenewswire.com

Relmada Therapeutics (NASDAQ:RLMD) Share Price Crosses Above Fifty Day Moving Average - Time to Sell?

November 3, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (RLMD) - What Are Investment Firms Thinking About This Stock?

October 31, 2026 | marketbeat.com

RLMD Share News Today

October 4, 2026 | uk.investing.com

Relmada Therapeutics consensus price target decreased by 13.31% to $10.96

October 2, 2026 | msn.com

Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement

September 14, 2026 | seekingalpha.com

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

September 14, 2026 | zacks.com

Insider Buying: Relmada Therapeutics (NASDAQ:RLMD) CFO Buys $339,150.00 in Stock

September 12, 2026 | insidertrades.com

Relmada Therapeutics Announces Urology Chief Medical Officer Exit

September 8, 2026 | tipranks.com

Relmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watch

September 2, 2026 | tipranks.com

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

September 1, 2026 | globenewswire.com

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

August 31, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ, GYRE, RLMD, and EOLS Company Descriptions

Evolus NASDAQ:EOLS

$6.96 -0.22 (-3.06%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$6.96 0.00 (-0.07%)

As of 11/13/2026 07:30 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Gyre Therapeutics NASDAQ:GYRE

$4.31 +0.01 (+0.23%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$4.30 0.00 (-0.12%)

As of 11/13/2026 07:30 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

LENZ Therapeutics NASDAQ:LENZ

$4.13 +0.04 (+0.98%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$4.17 +0.04 (+1.04%)

As of 11/13/2026 07:53 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Relmada Therapeutics NASDAQ:RLMD

$4.21 +0.05 (+1.20%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$4.22 +0.00 (+0.12%)

As of 11/13/2026 07:30 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LENZ, GYRE, RLMD, and EOLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LENZ, GYRE, RLMD, and EOLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LENZ, GYRE, RLMD, and EOLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ, GYRE, RLMD, and EOLS Company Descriptions

Evolus NASDAQ:EOLS

Gyre Therapeutics NASDAQ:GYRE

LENZ Therapeutics NASDAQ:LENZ

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LENZ, GYRE, RLMD, and EOLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LENZ, GYRE, RLMD, and EOLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LENZ, GYRE, RLMD, and EOLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ, GYRE, RLMD, and EOLS Company Descriptions

Evolus NASDAQ:EOLS

Gyre Therapeutics NASDAQ:GYRE

LENZ Therapeutics NASDAQ:LENZ

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools